Hilltop Holdings Inc. Raises Stock Holdings in Amgen Inc. $AMGN

Hilltop Holdings Inc. grew its position in Amgen Inc. (NASDAQ:AMGN) by 77.2% in the 1st quarter, Holdings Channel.com reports. The fund owned 6,089 shares of the medical research company’s stock after acquiring an additional 2,653 shares during the quarter. Hilltop Holdings Inc.’s holdings in Amgen were worth $2,142,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Morningstar Investment Management LLC grew its position in shares of Amgen by 8.0% during the first quarter. Morningstar Investment Management LLC now owns 14,529 shares of the medical research company’s stock worth $5,112,000 after acquiring an additional 1,081 shares during the last quarter. Public Employees Retirement System of Ohio raised its position in Amgen by 1.3% in the 1st quarter. Public Employees Retirement System of Ohio now owns 221,647 shares of the medical research company’s stock valued at $77,986,000 after purchasing an additional 2,766 shares during the last quarter. FCA Corp TX raised its position in Amgen by 2.1% in the 1st quarter. FCA Corp TX now owns 18,432 shares of the medical research company’s stock valued at $6,485,000 after purchasing an additional 376 shares during the last quarter. Compound Planning Inc. boosted its stake in Amgen by 83.4% during the 1st quarter. Compound Planning Inc. now owns 17,195 shares of the medical research company’s stock worth $6,050,000 after purchasing an additional 7,818 shares during the period. Finally, Klingman & Associates LLC boosted its stake in Amgen by 3.5% during the 1st quarter. Klingman & Associates LLC now owns 2,097 shares of the medical research company’s stock worth $738,000 after purchasing an additional 71 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.85% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research analysts have commented on AMGN shares. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Guggenheim increased their target price on shares of Amgen from $340.00 to $343.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Finally, Argus dropped their price target on Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, May 20th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $356.62.

Amgen Stock Performance

NASDAQ:AMGN opened at $376.04 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The firm has a market cap of $202.95 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 3.76 and a beta of 0.41. The firm’s fifty day moving average price is $351.28 and its 200 day moving average price is $351.80. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the firm earned $4.90 EPS. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts expect that Amgen Inc. will post 22.31 EPS for the current year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.